Liu M, Miguel R, Quispe Calla N, Aceves K, Fritts L, Miller C
Tissue Barriers. 2023; 12(1):2186672.
PMID: 36899465
PMC: 10832912.
DOI: 10.1080/21688370.2023.2186672.
Deese J, Brache V, Bahamondes L, Salinas A, Jorge A, Veiga Jr N
EClinicalMedicine. 2022; 44:101273.
PMID: 35128365
PMC: 8804165.
DOI: 10.1016/j.eclinm.2022.101273.
Halpern V, Fuchs R, Brache V, Bahamondes L, Miranda M, Lendvay A
Contracept X. 2021; 3:100070.
PMID: 34746745
PMC: 8551587.
DOI: 10.1016/j.conx.2021.100070.
Bick A, Louw-du Toit R, Skosana S, Africander D, Hapgood J
Pharmacol Ther. 2020; 222:107789.
PMID: 33316287
PMC: 8122039.
DOI: 10.1016/j.pharmthera.2020.107789.
Quispe Calla N, Miguel R, Fritts L, Miller C, Aceves K, Cherpes T
Biol Reprod. 2020; 103(2):310-317.
PMID: 32542371
PMC: 7401374.
DOI: 10.1093/biolre/ioaa105.
Zim CHIC: A cohort study of immune changes in the female genital tract associated with initiation and use of contraceptives.
Achilles S, Meyn L, Mhlanga F, Matubu A, Stoner K, Beamer M
Am J Reprod Immunol. 2020; 84(3):e13287.
PMID: 32533883
PMC: 7507197.
DOI: 10.1111/aji.13287.
Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out.
Hapgood J
AIDS Res Hum Retroviruses. 2019; 36(5):357-366.
PMID: 31797677
PMC: 7232639.
DOI: 10.1089/AID.2019.0228.
Depot-medroxyprogesterone acetate reduces genital cell-cell adhesion molecule expression and increases genital herpes simplex virus type 2 infection susceptibility in a dose-dependent fashion.
Quispe Calla N, Miguel R, Aceves K, Torres A, Cherpes T
Contraception. 2019; 100(5):397-401.
PMID: 31302121
PMC: 6875619.
DOI: 10.1016/j.contraception.2019.07.003.
The contraceptive medroxyprogesterone acetate, unlike norethisterone, directly increases R5 HIV-1 infection in human cervical explant tissue at physiologically relevant concentrations.
Ray R, Maritz M, Avenant C, Tomasicchio M, Dlamini S, van der Spuy Z
Sci Rep. 2019; 9(1):4334.
PMID: 30867477
PMC: 6416361.
DOI: 10.1038/s41598-019-40756-7.
HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa.
Heffron R, Stalter R, Pyra M, Nanda K, Erikson D, Hladik F
AIDS. 2018; 33(4):735-744.
PMID: 30585845
PMC: 6399047.
DOI: 10.1097/QAD.0000000000002123.
Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women.
Heffron R, Achilles S, Dorflinger L, Hapgood J, Kiarie J, Polis C
Contraception. 2018; 99(4):199-204.
PMID: 30576636
PMC: 6467541.
DOI: 10.1016/j.contraception.2018.12.001.
The Injectable Contraceptive Medroxyprogesterone Acetate Attenuates Mycobacterium tuberculosis-Specific Host Immunity Through the Glucocorticoid Receptor.
Tomasicchio M, Davids M, Pooran A, Theron G, Smith L, Semple L
J Infect Dis. 2018; 219(8):1329-1337.
PMID: 30452655
PMC: 6452311.
DOI: 10.1093/infdis/jiy657.
Task-shifting the provision of DMPA-SC in the DR Congo: Perspectives from two different groups of providers.
Hernandez J, Akilimali P, Glover A, Emel R, Mwembo A, Bertrand J
Contraception. 2018; 98(5):449-453.
PMID: 30031000
PMC: 6197837.
DOI: 10.1016/j.contraception.2018.07.002.
Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels.
Maritz M, Ray R, Bick A, Tomasicchio M, Woodland J, Govender Y
PLoS One. 2018; 13(4):e0196043.
PMID: 29698514
PMC: 5919616.
DOI: 10.1371/journal.pone.0196043.